Bluestone Jeffrey 4

What Happened
Jeffrey Bluestone, a director of Gilead Sciences (GILD), received two equity awards on April 30, 2026: 1,146 restricted stock units (RSUs) and a derivative award covering 4,884 shares (stock options). Both awards were granted at $0.00 per share and vested immediately on the grant date. The filing reports acquisition-type transactions; no shares were reported sold and no cash was paid for the awards.

Key Details

• Transaction date: April 30, 2026; Form 4 filed May 4, 2026 (filing appears timely).
• RSUs: 1,146 RSUs granted (F1). Each RSU represents a contingent right to one share; the RSUs vested immediately.
• Derivative award: 4,884 derivative shares reported as acquired (F2). Footnote states 100% of the shares subject to the stock option vested immediately.
• Reported acquisition price: $0.00 for both items (typical for grants).
• Shares owned after the transaction: not specified in the provided filing excerpt.
• No indication of a 10b5-1 plan, sale, or tax-withholding disposition in the supplied notes.

Context

• RSUs: when vested, RSUs convert into the right to receive shares (or settle in stock/cash per plan terms); this filing records the grant and immediate vesting, not a sale.
• Stock options (derivative): immediate vesting means the options are no longer subject to a vesting schedule; the filing does not show an exercise (no shares sold or exercised reported).
• For retail investors: grants and immediate vesting are routine compensation actions for executives and directors and do not, by themselves, indicate buying or selling conviction.